MX2010003815A - Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2. - Google Patents

Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.

Info

Publication number
MX2010003815A
MX2010003815A MX2010003815A MX2010003815A MX2010003815A MX 2010003815 A MX2010003815 A MX 2010003815A MX 2010003815 A MX2010003815 A MX 2010003815A MX 2010003815 A MX2010003815 A MX 2010003815A MX 2010003815 A MX2010003815 A MX 2010003815A
Authority
MX
Mexico
Prior art keywords
bcl
antibody
type
active agent
combination therapy
Prior art date
Application number
MX2010003815A
Other languages
English (en)
Inventor
Pablo Umana
Thomas Friess
Christian Klein
Pamela Braemer
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38904707&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003815(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MX2010003815A publication Critical patent/MX2010003815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

La presente invención se refiere al uso de un anticuerpo anti-CD2O de tipo II para la fabricación de un medicamento destinado al tratamiento del cáncer, en especial de los cánceres que expresan al CD20, en combinación con un agente activo anti-Bcl-2.
MX2010003815A 2007-10-15 2008-10-13 Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2. MX2010003815A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07020120 2007-10-15
PCT/EP2008/008635 WO2009049841A1 (en) 2007-10-15 2008-10-13 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent

Publications (1)

Publication Number Publication Date
MX2010003815A true MX2010003815A (es) 2010-08-04

Family

ID=38904707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003815A MX2010003815A (es) 2007-10-15 2008-10-13 Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.

Country Status (16)

Country Link
US (6) US20090098118A1 (es)
EP (2) EP2604277A1 (es)
JP (1) JP5416124B2 (es)
KR (1) KR101278395B1 (es)
CN (1) CN101827611B (es)
AR (1) AR068862A1 (es)
AU (1) AU2008314068B2 (es)
BR (1) BRPI0818673A2 (es)
CA (1) CA2702300A1 (es)
CL (1) CL2008003035A1 (es)
IL (1) IL204744A0 (es)
MX (1) MX2010003815A (es)
PE (1) PE20090966A1 (es)
RU (1) RU2541805C2 (es)
TW (1) TWI430809B (es)
WO (1) WO2009049841A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2380911T1 (en) * 2003-11-05 2018-07-31 Roche Glycart Ag ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION
US20110021440A1 (en) * 2007-05-16 2011-01-27 University Of Maryland, Baltimore Apoptotic pathway targeting for the diagnosis and treatment of cancer
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010043582A1 (en) * 2008-10-17 2010-04-22 Santaris Pharma A/S Method for the treatment of cancer
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
SG175253A1 (en) * 2009-05-26 2011-11-28 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2515883A4 (en) * 2009-12-22 2013-07-17 Abbvie Inc CAPSULE OF ABT-263
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012021486A2 (en) * 2010-08-09 2012-02-16 University Of South Florida Acylsulfonamides and processes for producing the same
WO2012020038A1 (en) 2010-08-13 2012-02-16 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
CA2819436A1 (en) * 2010-12-16 2012-06-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
KR101274731B1 (ko) * 2011-01-18 2013-06-18 동아대학교 산학협력단 레스베라트롤의 유사체인 ｈｓ－１７９３ 또는 이의 약학적으로 허용가능한 염을 유효성분으로 하는 전립선 암 치료용 약학적 조성물
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CN102222176A (zh) * 2011-06-01 2011-10-19 山东大学 一种快速发现以Bcl-2蛋白为靶点的先导化合物的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
JP6408993B2 (ja) * 2012-09-07 2018-10-17 ジェネンテック， インコーポレイテッド タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US20150313906A1 (en) * 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2984706A1 (en) * 2015-05-26 2016-12-01 F. Hoffmann-La Roche Ag Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
TR201703149A2 (tr) * 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN110869391A (zh) * 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
GEP20237460B (en) * 2018-07-31 2023-01-25 Ascentage Pharma Suzhou Co Ltd Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab and/or bendamustine or bcl-2 inhibitor combined with chop
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN115996760A (zh) * 2020-04-27 2023-04-21 阿鲁纳生物股份公司 用于中枢神经***递送的结合剂及其用途
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US371191A (en) 1887-10-11 Cloth-sponging machine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0722342B1 (en) 1993-09-20 2004-12-29 The Trustees Of The University Of Pennsylvania REGULATION OF bcl-2 GENE EXPRESSION
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
ATE458007T1 (de) * 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
EP1080113A4 (en) 1998-05-15 2002-04-17 Imclone Systems Inc TREATMENT OF HUMAN TUMORS USING RADIATION AND GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
NZ581541A (en) 2002-10-17 2011-07-29 Genmab As Human monoclonal antibodies against CD20
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
WO2004056971A2 (en) 2002-12-19 2004-07-08 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
PL224786B1 (pl) 2003-01-22 2017-01-31 Glycart Biotechnology Ag Wyizolowany kwas nukleinowy, ssaczy wektor ekspresyjny, komórki gospodarza, fuzja polipeptydowa i sposób jej wytwarzania, sposoby in vitro i ex vivo modyfikowania profilu glikozylacji polipeptydu wytwarzanego przez komórki gospodarza
KR101168441B1 (ko) 2003-05-30 2012-07-25 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 암 또는 바이러스 질환의 치료를 위한 삼복소환 화합물,조성물 및 방법
EP2236172A1 (en) * 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
SI2380911T1 (en) * 2003-11-05 2018-07-31 Roche Glycart Ag ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION
EA011218B1 (ru) * 2004-03-25 2009-02-27 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Сокристаллы госсипола и их применение
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP1853255A4 (en) 2005-02-22 2009-07-08 Gemin X Pharmaceuticals Canada METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
CN101175738B (zh) * 2005-05-12 2010-10-27 雅培制药有限公司 细胞凋亡促进剂
BRPI0611220A2 (pt) * 2005-06-02 2010-08-24 Astrazeneca Ab anticorpos direcionados para cd20 e usos dos mesmos
NO345919B1 (no) 2005-08-26 2021-10-18 Roche Glycart Ag Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet

Also Published As

Publication number Publication date
CA2702300A1 (en) 2009-04-23
CL2008003035A1 (es) 2010-01-11
AR068862A1 (es) 2009-12-09
EP2604277A1 (en) 2013-06-19
CN101827611A (zh) 2010-09-08
TW200920401A (en) 2009-05-16
IL204744A0 (en) 2010-11-30
CN101827611B (zh) 2014-01-15
US20110086025A1 (en) 2011-04-14
WO2009049841A1 (en) 2009-04-23
EP2203185A1 (en) 2010-07-07
RU2010118448A (ru) 2012-05-20
PE20090966A1 (es) 2009-07-13
US20150056186A1 (en) 2015-02-26
AU2008314068A1 (en) 2009-04-23
KR101278395B1 (ko) 2013-06-24
AU2008314068B2 (en) 2014-01-16
TWI430809B (zh) 2014-03-21
BRPI0818673A2 (pt) 2015-09-08
JP5416124B2 (ja) 2014-02-12
US20140004104A1 (en) 2014-01-02
KR20100056559A (ko) 2010-05-27
US20120276085A1 (en) 2012-11-01
US20110287006A1 (en) 2011-11-24
JP2011500521A (ja) 2011-01-06
US20090098118A1 (en) 2009-04-16
RU2541805C2 (ru) 2015-02-20

Similar Documents

Publication Publication Date Title
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
MX2010004164A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma.
MY163003A (en) Combination theraphy of an afucosylated cd20 antibody with bendamustine
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
MX2012001783A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona.
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
UA108618C2 (uk) Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
PH12016500839A1 (en) Combination theraphy of an anti cd20 antibody with a btk inhibitor
NZ587706A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
MY163544A (en) Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2010006991A (es) Tratamientos de cancer terapeuticos.
MX2015015091A (es) Terapia de combinacion de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-farmaco.
NZ711867A (en) Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
MX2009010271A (es) Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana.
MX2012012118A (es) Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
MX2020001727A (es) Terapia de combinacion.
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
EA201200190A1 (ru) Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
MX2010009697A (es) Tratamientos anticancerigenos mejorados.
WO2012158776A3 (en) Combination therapy for treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration